Ann: Trading Halt, page-104

I must say that it is disappointing to have a raise now, as it appeared RAC were on the verge of entering a key growth phase after 9 months of consolidation. Despite this, I fully understand why it has to be done, as we need to maintain our current velocity of being the first m6A mRNA epitranscriptomic modulator available to market. I think that this is a very exciting time for RAC holders, as this raising will likely be the last needed to realise our goal of a buyout, with potential that has become staggering to comprehend given the most recent discoveries of heart safety.

I will provide an example to demonstrate how enormous this opportunity is to holders on this forum.

Assuming the combination of Zantrene+Doxorubicin totals $5000 ($4940 and $60 attributed to Zantrene and generic Doxorubicin, respectively) per patient. If Zantrene is used in 100% of patients receiving Doxorubicin (3M), then the yearly revenue for Zantrene will be USD $14.8B (AUD $20.58B). In the context of share price, the yearly revenue for Zantrene devided by an assumed 200M shares on issue (fully diluted) would be AUD $102.9 per share for doxorubicin patients alone. These figures do not take into consideration other anthracyclines OR the enormous potential from FTO directed therapies.

I 100% believe in this company and the science, and as such, I'll be trying to obtain the full allocation from this raise at $3 without selling a single share. RAC is the most undervalued stock on the ASX.